argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
14 apr 2015 - 07:15
Statutaire naam
argenx SE
Titel
arGEN-x N.V. Announces Changes to the Board of Directors
Bericht
Breda, the Netherlands/Ghent, Belgium, 14 April 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announces the resignation of non-executive directors Bruno Montanari and Harrold van Barlingen from the Board of Directors per 13 May 2015.
Datum laatste update: 26 december 2025